Zydus Lifes gets nil observations after USFDA's inspection of Injectables unit in Ahmedabad

Zydus Lifesciences said in the filing on Tuesday that the group’s injectables manufacturing facility at Zydus Biotech Park in Changodar in Ahmedabad underwent USFDA inspection from 5 th June to 13 June 2023. 

The CGMP inspection concluded with nil observations.

Further, the company said it has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg (USRLD: Arthrotec® Delayed-Release Tablets).

The group now has 373 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04, the company said.

Source: Media reports

Related Blogs
blog-logo

Share Market

blog-logo

12 mins read . 12 Jul 2024

Ritesh Agarwal: The OYO Founder’s Success Story

  • 0 people read
blog-logo

Share Market

blog-logo

15 mins read . 08 Jul 2024

Best Oil & Gas Stocks in India

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions